Jeremy Shefner, MD, PhD
Jeremy Shefner, MD, PhD, is a board-certified neurologist specializing in amyotrophic lateral sclerosis (ALS) and neuromuscular disorders.
Dr. Shefner’s research focuses on biomarker development and the clinical therapeutics of ALS and spinal muscular atrophy. He co-founded the Northeast ALS Clinical Trials Consortium (NEALS), the largest and most active consortium in the world dedicated to ALS. He continues to direct the NEALS outcomes and clinical monitoring cores and is currently the principal investigator for two multi-center clinical trials, as well as a biomarker study evaluating the effectiveness of electrical impedance myography in measuring ALS disease progression.
Dr. Shefner has published approximately 200 papers in peer-reviewed journals and has served on multiple grant review panels. He has also participated in committees organized by the Institute of Medicine to investigate the relationship between military service and ALS, as well as the health effects of Agent Orange on Vietnam War veterans. In 2014, Dr. Shefner received the Sheila Essey Award for ALS Research, presented annually by the American Academy of Neurology and the ALS Association.
Dr. Shefner received his PhD in sensory physiology from the University of Illinois in Urbana-Champaign, and his MD from Northwestern University Medical School in Chicago. He completed his residency training at the Harvard Longwood Neurology Training Program in Boston and completed a fellowship in neuromuscular disease at the Brigham and Women’s Hospital in Boston.